Denosumab, a monoclonal antibody that targets RANKL, and romosozumab, a monoclonal antibody that inhibits sclerostin, have both been approved for the treatment of osteoporosis and have demonstrated significant benefits in increasing bone density and reducing fracture risk (3, 4). This evidence concerns the gene TNFSF11 and osteoporosis.